SA517380842B1 - بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام - Google Patents

بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام

Info

Publication number
SA517380842B1
SA517380842B1 SA517380842A SA517380842A SA517380842B1 SA 517380842 B1 SA517380842 B1 SA 517380842B1 SA 517380842 A SA517380842 A SA 517380842A SA 517380842 A SA517380842 A SA 517380842A SA 517380842 B1 SA517380842 B1 SA 517380842B1
Authority
SA
Saudi Arabia
Prior art keywords
interleukin
polypeptide
fusion protein
receptor alpha
methods
Prior art date
Application number
SA517380842A
Other languages
Arabic (ar)
English (en)
Inventor
توماس ماليك
Original Assignee
يونيفيرستى اوف ميامى
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA517380842(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by يونيفيرستى اوف ميامى filed Critical يونيفيرستى اوف ميامى
Publication of SA517380842B1 publication Critical patent/SA517380842B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
SA517380842A 2014-08-06 2017-02-05 بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام SA517380842B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
SA517380842B1 true SA517380842B1 (ar) 2021-12-26

Family

ID=53836871

Family Applications (1)

Application Number Title Priority Date Filing Date
SA517380842A SA517380842B1 (ar) 2014-08-06 2017-02-05 بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام

Country Status (32)

Country Link
US (3) US12084483B2 (enExample)
EP (2) EP3177307B1 (enExample)
JP (3) JP6723982B2 (enExample)
KR (1) KR102653758B1 (enExample)
CN (2) CN107074967B (enExample)
AU (3) AU2015301071C1 (enExample)
BR (1) BR112017001940A2 (enExample)
CA (1) CA2957273C (enExample)
CL (1) CL2017000284A1 (enExample)
CO (1) CO2017002166A2 (enExample)
DK (1) DK3177307T3 (enExample)
EA (2) EA202091342A3 (enExample)
ES (1) ES2986097T3 (enExample)
FI (1) FI3177307T3 (enExample)
HR (1) HRP20241258T1 (enExample)
HU (1) HUE068478T2 (enExample)
IL (2) IL250007B (enExample)
LT (1) LT3177307T (enExample)
MA (2) MA40094B1 (enExample)
MX (1) MX388977B (enExample)
MY (1) MY180831A (enExample)
PE (1) PE20170503A1 (enExample)
PH (1) PH12017500042A1 (enExample)
PT (1) PT3177307T (enExample)
RS (1) RS65930B1 (enExample)
SA (1) SA517380842B1 (enExample)
SG (2) SG11201700706WA (enExample)
SI (1) SI3177307T1 (enExample)
SM (1) SMT202400414T1 (enExample)
TN (1) TN2017000020A1 (enExample)
WO (1) WO2016022671A1 (enExample)
ZA (1) ZA201700245B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
LT3102595T (lt) 2014-02-06 2019-01-25 F. Hoffmann-La Roche Ag Interleukino-2 sulieti baltymai ir jų panaudojimas
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
US12202856B2 (en) * 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
KR20190057113A (ko) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019113221A1 (en) 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019183389A1 (en) * 2018-03-23 2019-09-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
EP3941935A1 (en) * 2019-03-18 2022-01-26 Biontech Cell & Gene Therapies Gmbh Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3976638A4 (en) * 2019-05-24 2023-08-23 Proviva Therapeutics (Hong Kong) Limited IL-2 COMPOSITIONS AND METHODS OF USE THEREOF
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
AU2020315282A1 (en) * 2019-07-12 2022-02-10 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
AU2020316002A1 (en) * 2019-07-25 2022-03-03 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
US20220378933A1 (en) * 2019-09-19 2022-12-01 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
KR20220084066A (ko) * 2019-10-18 2022-06-21 엘커메스 파마 아일랜드 리미티드 면역 체크포인트 억제제와 조합된 면역조절성 il-2 제제
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021222762A2 (en) 2020-04-30 2021-11-04 Aetio Biotherapy, Inc. Activatable il2 composition and methods of use
WO2022036079A1 (en) * 2020-08-13 2022-02-17 Bristol-Myers Squibb Company Methods of redirecting of il-2 to target cells of interest
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
AU2023219190A1 (en) * 2022-02-11 2024-08-15 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy
EP4479090A4 (en) * 2022-02-16 2025-08-27 Univ Miami IL-2 AND TL1A FUSION PROTEINS AND METHODS OF USE THEREOF
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
CN120752258A (zh) * 2023-02-22 2025-10-03 百奥赛图(北京)医药科技股份有限公司 抗il2ra抗体及其用途
WO2025207491A1 (en) * 2024-03-25 2025-10-02 Mural Oncology, Inc. Compositions and methods for cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2619719B1 (fr) 1987-09-01 1991-05-10 Sanofi Sa Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
ES2196098T3 (es) * 1994-12-28 2003-12-16 Univ Kentucky Res Found Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6967092B1 (en) * 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
JPWO2003029475A1 (ja) 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
RU2006135112A (ru) 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
WO2012088383A2 (en) 2010-12-23 2012-06-28 Genentech, Inc. PILR alpha INTERACTIONS AND METHODS OF MODIFYING SAME
SI3401402T1 (sl) * 2012-06-08 2021-03-31 Alkermes Pharma Ireland Limited Ligandi modificirani s krožno permutacijo kot agonisti in antagonisti
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
KR102653758B1 (ko) 2024-04-04
TN2017000020A1 (en) 2018-07-04
NZ766851A (en) 2024-07-26
DK3177307T3 (da) 2024-10-07
EP3177307A1 (en) 2017-06-14
EP4438621A2 (en) 2024-10-02
AU2022204034A1 (en) 2022-07-14
WO2016022671A1 (en) 2016-02-11
PT3177307T (pt) 2024-09-13
MA40721B1 (fr) 2024-08-30
ZA201700245B (en) 2024-06-26
JP7272663B2 (ja) 2023-05-12
US20230079120A1 (en) 2023-03-16
JP2017523789A (ja) 2017-08-24
EA202091342A2 (ru) 2020-11-30
SG11201700706WA (en) 2017-02-27
AU2020203352B2 (en) 2022-03-10
CN107074967B (zh) 2021-06-08
LT3177307T (lt) 2024-08-12
CO2017002166A2 (es) 2017-05-19
HRP20241258T1 (hr) 2024-12-06
MA40094A1 (fr) 2021-09-30
AU2020203352A1 (en) 2020-07-02
US20170233448A1 (en) 2017-08-17
RS65930B1 (sr) 2024-10-31
SG10201913695PA (en) 2020-03-30
MY180831A (en) 2020-12-10
CN107074967A (zh) 2017-08-18
NZ728042A (en) 2024-07-26
AU2015301071A1 (en) 2017-02-02
IL275944B (en) 2022-02-01
PH12017500042A1 (en) 2017-05-22
EP4438621A3 (en) 2024-12-18
SMT202400414T1 (it) 2024-11-15
MX2017001062A (es) 2017-07-14
PE20170503A1 (es) 2017-05-11
EA202091342A3 (ru) 2020-12-30
BR112017001940A2 (pt) 2017-11-28
MA40721A (fr) 2017-06-13
JP2021000084A (ja) 2021-01-07
IL250007A0 (en) 2017-03-30
ES2986097T3 (es) 2024-11-08
CN113912737A (zh) 2022-01-11
IL275944A (en) 2020-08-31
SI3177307T1 (sl) 2024-09-30
MX388977B (es) 2025-03-20
EA201790063A1 (ru) 2017-06-30
EA035956B1 (ru) 2020-09-04
CL2017000284A1 (es) 2017-11-17
IL250007B (en) 2020-07-30
JP6723982B2 (ja) 2020-07-15
EP3177307B1 (en) 2024-07-17
AU2015301071C1 (en) 2020-07-02
HUE068478T2 (hu) 2025-01-28
MA40094B1 (fr) 2022-05-31
US20250163118A1 (en) 2025-05-22
CA2957273C (en) 2023-03-14
JP2023099045A (ja) 2023-07-11
US12084483B2 (en) 2024-09-10
AU2015301071B2 (en) 2020-03-05
FI3177307T3 (fi) 2024-10-04
KR20170030646A (ko) 2017-03-17
CA2957273A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PH12018501882A1 (en) Binding proteins and methods of use thereof
MY202933A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
IL275779A (en) Recombinant human sialidases, sialidase-related proteins and methods of using them
EA201591331A1 (ru) Антагонисты il-33 и их применение
MX388594B (es) Proteinas de fusion.
MY191944A (en) Binding proteins and methods of use thereof
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
MX382518B (es) Antigenos de citomegalovirus y su uso.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2019012419A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
EP3374379A4 (en) N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
MY191217A (en) Group a streptococcus vaccine
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
TH1701000601A (th) ฟิวชันโปรตีนของอินเตอร์ลูคิน-2/อินเตอร์ลูคิน-2 รีเซปเตอร์แอลฟา และวิธีการใช้
HK1231753A1 (en) Methods for activating t cells using an inducible chimeric polypeptide
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
TH1501005499A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้
RU2013131997A (ru) НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2)